News | Artificial Intelligence | November 05, 2022

Guerbet announced an agreement with Merative, formalizing the termination of their collaboration signed in July 2018

Guerbet announced an agreement with Merative, formalizing the termination of their collaboration signed in July 2018.

Nov. 4, 2022 — Guerbet announced an agreement with Merative formalizing the termination of their collaboration initiated in July 2018. This partnership aimed to design, develop and market software solutions to help diagnose and monitor liver and prostate cancers. The termination follows Merative's strategic shift in how it delivers artificial intelligence within its imaging product portfolio.The new Asset Assignment and License Agreement grants Guerbet the ability and autonomy to pursue research and development, and plan for the market launch of artificial intelligence solutions. Assets developed during the partnership, including source code for application software, Artificial Intelligence algorithms and the associated intellectual property, are being transferred to Guerbet. The market potential remains unchanged and significant, and this Asset Assignment and License Agreement will transfer control over the remaining development work to Guerbet. Promising initial results have been obtained in 2022, particularly for the detection of liver lesions (presentation scheduled for the RSNA 2022 conference) and for the detection of prostate cancer (work presented at the ECR 2022 conference). The high quality of the work presented by Guerbet’s Artificial Intelligence research team also impressed the jury of the BPI France 2030 program, which has awarded the company €1 million in funding for its project aimed at early detection of pancreatic cancer, as recently announced. Numerous stakeholders have communicated their interest to the Group’s management in recent months, attesting to the business’ strong potential. Constructive discussions are currently also underway to set up new partnerships in order to accelerate the business roadmap and to facilitate the emergence of a national champion in the area of artificial intelligence for medical imaging.

For more information: www.guerbet.com

Find more RSNA22 coverage here 


Related Content

News | Magnetic Resonance Imaging (MRI)

November 30, 2023 — Royal Philips, a global leader in health technology, today launched three new fit for purpose MR ...

Time November 30, 2023
arrow
News | Radiology Imaging

November 30, 2023 — Through its leading imaging solutions and commitment to innovation, GE HealthCare remains at the ...

Time November 30, 2023
arrow
News | RSNA

November 30, 2023 — Hologic, Inc. showcased several recent developments in next-generation AI solutions at the 109th ...

Time November 30, 2023
arrow
News | Pediatric Imaging

November 30, 2023 — Youth baseball players are prone to elbow pain and injuries, including repetitive overuse changes ...

Time November 30, 2023
arrow
News | RSNA

November 30, 2023 — Breast cancer mortality is significantly reduced when women regularly attend screening mammograms ...

Time November 30, 2023
arrow
News | Artificial Intelligence

November 29, 2023 — The Radiological Society of North America (RSNA) has announced the results of the “RSNA Abdominal ...

Time November 29, 2023
arrow
News | Artificial Intelligence

November 29, 2023 —Flywheel, a leading medical imaging artificial intelligence (AI) development platform, today ...

Time November 29, 2023
arrow
News | Contrast Media

November 29, 2023 — Bayer continues to advance its comprehensive Radiology portfolio with progress in the development ...

Time November 29, 2023
arrow
News | RSNA

November 28, 2023 — Curtis P. Langlotz, MD, PhD, has taken the helm as 2023-2024 president of the Radiological Society ...

Time November 29, 2023
arrow
News | Pediatric Imaging

November 29, 2023 — Using artificial intelligence (AI) to analyze specialized brain MRI scans of adolescents with and ...

Time November 29, 2023
arrow
Subscribe Now